
Pipeline

CT0532
Global3
Phase II/III

CT053 is a BCMA-specific CAR T product candidate, consists of autologous T cells genetically modified with a CAR incorporating a fully human anti-BCMA single chain fragment variant with high binding affinity that specifically recognizes BCMA.

Investigator-Initiated Trial in China
Phase I/II Clinical Trial for MM in China (LUMMICAR STUDY 1)

for relapsed and/or refractory multiple myeloma (R/R MM)

for relapsed and/or refractory multiple myeloma (R/R MM)

Breakthrough Therapy Designation, NMPA
for relapsed and/or refractory multiple myeloma (R/R MM)

for multiple myeloma (MM)

Orphan Drug designation, EMA
for multiple myeloma (MM)
CT041
Global
Phase II/III

CT041 is an autologous CAR T product candidate that targets Claudin18.2 (“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.

Investigator-initiated trials
Phase Ib clinical trial for advanced GC/GEJ and PC
Confirmatory Phase II clinical trial for advanced GC/GEJ

for advanced gastric /gastroesophageal junction adenocarcinoma (GC/GEJ) with Claudin18.2-positive tumor

for advanced gastric cancer

for gastric /gastroesophageal junction cancer (GC/GEJ)

Orphan Drug designation, EMA
for advanced gastric cancer
Phase II/III

CT011 is an autologous CAR T product candidate that targets glypican-3 (GPC3), which is highly expressed in HCC and is suggested to be a prognostic marker for the disease.

Investigator-Initiated Trial for HCC
Phase I Clinical Trial for HCC
CT032
Global3
Phase II/III

CT01804
Global
Phase II/III

CT01814
Global
Phase II/III

CT05905
Global
Phase II/III

Phase II/III

KJ-C1807(CT048)6
Global
Phase II/III

KJ-C21136
Global
Phase II/III

KJ-C21145
Global
Phase II/III


AB011
Phase II/III

AB011 is a humanized monoclonal antibody product candidate that targets Claudin18.2(“CLDN18.2”), which is a stomach-specific isoform of CLDN18 and is highly expressed in gastric and pancreatic cancer cells.

Phase I Clinical Trial for CLDN18.2 Positive Advanced Solid Tumors
1 Phase II trials of some indications are pivotal studies
2 Core Product Candidate
3 Commercial rights in mainland China have been granted to Huadong Medicine (SZ: 000963). Rights in the South Korean market have been licensed out to HK Inno.N (KOSDAQ: 195940)
4 Developed with our sFv-ε-based T-cell therapy
5 Developed with our THANK-uCAR® technology
6 Developed with our CycloCAR® technology
R/R MM: relapsed / refractory multiple myeloma; GC: gastric cancer; GEJ: gastroesophageal junction cancer; PC: pancreatic cancer; B-NHL: B-cell non-Hodgkin lymphoma; HCC: hepatocellular carcinoma